Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Subscribe To Our Newsletter & Stay Updated
